乳腺癌早期的达托帕马巴-德鲁克斯:顺序多重分配随机I-SPY2.2第二阶段试验
Katia Khoury1, Jane L Meisel2, Christina Yau3
1University of Alabama at Birmingham, Birmingham, AL, USA.
Nature medicine
|September 14, 2024
概括
在高风险乳腺癌治疗中,达托帕马布-德鲁克斯泰干 (Dato-DXd) 显示出有前途. I-SPY2.2试验发现Dato-DXd在特定亚型中有效,达到41%的病理完整反应率,具有可控的毒性.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 以患者为中心的护理旨在提供个性化的治疗,并在癌症治疗中降低毒性.
- 该I-SPY2.2试验采用一种新的新辅助剂序列治疗设计,用于高风险的乳腺癌.
- 达托帕马布-德鲁克斯坦 (Dato-DXd) 是一种在这个适应性试验框架内测试的研究药物.
研究的目的:
- 在I-SPY2.2试验中,评估达托帕马布-德鲁克斯坦 (Dato-DXd) 作为新辅助治疗高风险的2/3期乳腺癌的疗效和安全性.
- 评估Dato-DXd在不同乳腺癌亚型中的性能,使用顺序性,适应性治疗策略.
- 确定特定的患者群体,其中Dato-DXd表现出显著的病理完整反应 (pCR).
主要方法:
- I-SPY2.2试验使用了一种连续的多重分配随机化设计,其中包括三块新辅助疗法.
- 患有高风险阶段2/3乳腺癌的患者随机分配在A块接受研究药物,包括Dato-DXd.
- 治疗决策以成像和活检数据为指导,预测响应者可以选择早期手术切除. 主要终点是pCR.
主要成果:
- 在任何乳腺癌亚型中,Dato-DXd在A区块后没有达到主要的成功值.
- 然而,使用Dato-DXd的整体治疗策略在荷尔蒙受体阴性,HER2,免疫,DNA修复缺陷亚型中取得了成功,pCR率为41%.
- 观察到的毒性通常是低级的,口炎和眼部事件是最常见的,并且没有出现新的安全问题.
结论:
- 在I-SPY2.2适应性试验中,达托帕马布-德鲁克斯泰干 (Dato-DXd) 显示出显著的活性,并且在特定的高风险乳腺癌亚型中耐受良好.
- 这些发现支持进一步调查Dato-DXd在荷尔蒙受体阴性/HER2-/免疫/DNA修复缺陷-乳腺癌特征中的作用.
- I-SPY2.2试验的自适应设计有效地确定了一组受益于Dato-DXd的患者,与个性化医疗目标保持一致.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


